On 16 July, the NMPA announced a new indication for Hengrui Pharma’s camrelizumab, approved in combination with famitinib for the first-line treatment of recurrent or metastatic cervical cancer — making it the first domestic PD-1 monoclonal antibody to receive first-line cervical cancer approval in China. The approval is based on the Phase 3 SHR-1210-III-329 registrational data, a multicenter study that enrolled 443 patients with a median follow-up of 19.3 months. Compared with standard platinum-containing chemotherapy, the immune-targeted combination regimen significantly extended survival: median PFS reached 11.1 months (versus 7.5 months with chemotherapy, a 32% reduction in the risk of progression), and median OS exceeded 34.4 months (versus 23.4 months with chemotherapy, a 35% reduction in the risk of death), with consistent benefit across the full study population and offering a new chemotherapy-free first-line option.
The camrelizumab plus famitinib combination has previously been approved in a later-line cervical cancer indication; this approval moves the regimen to an earlier line. Camrelizumab’s domestic indications now total 11, covering multiple solid tumors, further consolidating the lead position of domestic immune checkpoint inhibitors in gynecologic oncology and enriching the standardized treatment landscape for advanced cervical cancer.